Most conversations about PCOS treatment focus on the visible symptoms: irregular or absent periods, acne, unwanted hair growth, fertility challenges. These are real and deserve attention. But for the 70–80% of women with PCOS who also have insulin resistance, treating only the symptoms while leaving the underlying metabolic driver untouched is like painting over a water stain without fixing the leak.
GLP-1 receptor agonists — the class of medications that includes Ozempic, Wegovy, Mounjaro, and Zepbound — address insulin resistance directly. That is the mechanism that has made them clinically interesting for PCOS. This guide explains how the connection works, what the research shows, and what patients with PCOS and insulin resistance should know before exploring this option.
Why Insulin Resistance Is Central to PCOS
PCOS is not a single disease. It is a syndrome — a cluster of findings (elevated androgens, disrupted ovulation, polycystic ovaries) that can present very differently across patients. The unifying thread for a large proportion of PCOS cases is insulin resistance: a state in which cells become less responsive to insulin, requiring the pancreas to secrete progressively higher levels to maintain normal blood glucose.
This matters for PCOS because the ovaries are highly sensitive to insulin. When circulating insulin levels are chronically elevated, the ovaries respond by producing more androgens — testosterone, androstenedione, DHEA-S. Elevated androgens disrupt the hormonal signaling that coordinates ovulation. The follicle maturation process stalls, ovulation fails or becomes irregular, and the hormonal cycle becomes self-reinforcing: more androgens → more disrupted ovulation → more androgen accumulation.
The result is a metabolic-hormonal feedback loop. Breaking that loop — by improving insulin sensitivity — is the core rationale for using GLP-1 therapy in PCOS.
Insulin resistance in PCOS is not always obvious from a fasting glucose test. Many patients with significant insulin resistance have normal fasting glucose and even normal HbA1c. The most sensitive measure is fasting insulin combined with a calculated HOMA-IR score (fasting insulin in µU/mL × fasting glucose in mg/dL ÷ 405). A HOMA-IR above 2.0–2.5 is generally considered consistent with meaningful insulin resistance in the clinical context of PCOS.
How GLP-1 Medications Target Insulin Resistance
GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a naturally occurring gut hormone that is released after meals. Their metabolic effects are several:
Glucose-dependent insulin stimulation. GLP-1s prompt the pancreas to release insulin when blood glucose is elevated — and importantly, not when glucose is at baseline. This means they lower fasting insulin without the hypoglycemia risk associated with medications that stimulate insulin release independently of glucose levels.
Glucagon suppression. GLP-1 agonists suppress glucagon, the counter-regulatory hormone that signals the liver to release stored glucose. Lower glucagon means lower hepatic glucose output and therefore lower ambient insulin demand.
Weight loss. GLP-1 medications produce substantial, sustained weight loss — typically 10–15% of body weight with semaglutide and up to 20–22% with tirzepatide in obesity trials. Even modest weight reduction (5–7%) meaningfully reduces insulin resistance in most patients. The weight loss itself creates a second, powerful pathway to improved insulin sensitivity independent of the direct hormonal effects.
Reduced hepatic fat. Fatty infiltration of the liver worsens insulin resistance. GLP-1 therapy has been shown to reduce hepatic fat content independently of body weight change — which contributes to improved insulin sensitivity through a third mechanism.
The result, documented across multiple clinical studies, is a meaningful reduction in fasting insulin and HOMA-IR. In PCOS populations, this metabolic improvement is followed — with a lag of weeks to months — by reductions in circulating androgens and, in many patients, improvement in menstrual cycle regularity.
What the Research Shows in PCOS Populations
GLP-1 therapy for PCOS has been studied primarily with liraglutide (an older GLP-1 agonist) and, more recently, semaglutide. The evidence base continues to grow.
Semaglutide in PCOS. A 2023 randomized controlled trial published in Fertility and Sterility evaluated semaglutide versus placebo in women with PCOS over 24 weeks. The semaglutide group achieved significantly greater reductions in body weight, fasting insulin, HOMA-IR, and free testosterone compared to placebo. Improvements in menstrual cycle regularity were reported in a subset of patients, though this outcome is not universal.
Observational studies in PCOS populations have generally reported consistent improvements in insulin resistance markers within 12 weeks, with androgen reductions following at 12–24 weeks. The magnitude of androgen reduction tends to correlate with the magnitude of insulin improvement — supporting the mechanistic link between insulin and ovarian androgen production.
Liraglutide in PCOS. The most extensively studied GLP-1 for PCOS is liraglutide (Saxenda, Victoza). Multiple trials have shown improvements in weight, HOMA-IR, testosterone, and menstrual frequency. A landmark 2015 RCT and several subsequent studies have documented these effects. This liraglutide evidence base is what the scientific community drew on when extending interest to semaglutide — a more potent, longer-acting GLP-1 agonist.
Tirzepatide. Tirzepatide, the dual GIP/GLP-1 agonist in Mounjaro and Zepbound, has limited PCOS-specific published data as of 2026. Its dual mechanism may offer enhanced insulin sensitization compared to GLP-1 alone — GIP receptor activation in adipose tissue and other tissues complements the GLP-1 effects — but this advantage has not been specifically studied in PCOS populations. Extrapolations from the SURMOUNT trials (in general obesity populations) suggest larger weight loss and insulin improvement, which would be expected to translate to greater hormonal benefit. Clinical trials enrolling PCOS populations specifically are ongoing.
An important distinction. This post covers the insulin resistance angle in PCOS — a distinct focus from our detailed guide on choosing between semaglutide and tirzepatide for PCOS, which covers the drug comparison, head-to-head evidence, and cost breakdown side by side. If you are deciding which medication to explore, that guide covers the comparison in full.
Who Is Most Likely to Benefit
Not all PCOS presentations involve significant insulin resistance. The "lean PCOS" phenotype — women with PCOS who are not overweight and have relatively normal metabolic markers — may not benefit from GLP-1 therapy to the same degree as those with documented insulin resistance.
The patients most likely to see meaningful benefit from GLP-1 therapy for PCOS are those who:
- Have documented insulin resistance (HOMA-IR ≥ 2.0–2.5 or elevated fasting insulin)
- Carry excess weight, particularly central (abdominal) adiposity
- Have elevated androgens that have not normalized with weight loss alone
- Have tried metformin (the standard first-line insulin sensitizer for PCOS) with inadequate response
Metformin remains the first-line pharmacological option for insulin resistance in PCOS because it is inexpensive, well-studied, and off-patent. For patients who have had inadequate response to metformin — or whose degree of insulin resistance or weight burden warrants a more potent intervention — GLP-1 therapy represents a logical next step.
The two medications are sometimes used in combination. Metformin addresses insulin resistance through one mechanism (inhibiting hepatic glucose production); GLP-1 agonists address it through complementary mechanisms. Combined use is increasingly common in metabolic medicine practices, though PCOS-specific combination trial data is limited.
Off-Label Use: What Patients Need to Know
Neither semaglutide nor tirzepatide is FDA-approved for PCOS or insulin resistance as a standalone indication. When a provider prescribes either for this purpose, it is off-label use.
Off-label prescribing is legal and common in medicine — particularly in specialties like endocrinology, reproductive medicine, and metabolic health, where evidence accumulates faster than the regulatory approval process. Off-label prescribing is appropriate when: the evidence supports the clinical use, the provider can document the rationale, and the patient provides informed consent after understanding the distinction from approved use.
What patients should be clear on before proceeding:
- Insurance typically will not cover GLP-1s prescribed for PCOS
- The prescription requires a provider willing to document the clinical rationale
- Monitoring standards differ from on-label use — more lab follow-up is appropriate given the complexity of the metabolic presentation
Finding a Telehealth Provider
The standard GLP-1 telehealth platforms — those that process high volume of weight management patients — may not be well-suited to evaluate and manage PCOS with insulin resistance. They often lack the lab ordering workflows, the gynecological or endocrinological expertise, and the monitoring frameworks that PCOS management requires.
Better-fit providers include:
- Women's health telehealth platforms that specialize in hormonal and metabolic conditions
- Endocrinology or reproductive medicine telehealth services, where providers routinely evaluate insulin resistance markers
- Integrative or functional medicine providers who are comfortable with off-label metabolic prescribing and order comprehensive labs
When evaluating a provider, ask whether they can: order and interpret fasting insulin and HOMA-IR; monitor androgens and cycle changes over time; manage GLP-1 dose titration; and coordinate with your OB/GYN or reproductive endocrinologist if fertility is a goal.
If you are planning to conceive, note that GLP-1 medications are generally discontinued before attempting pregnancy. The timing of discontinuation should be discussed with your prescribing provider and reproductive specialist.
For a provider comparison by state, medication availability, and cost, use the TeleHealthAlly comparison tool.
Frequently Asked Questions
Is Ozempic approved for PCOS or insulin resistance?
No. GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not FDA-approved for PCOS or insulin resistance. Any prescription for these purposes is off-label use. Both are approved for type 2 diabetes and weight management (at appropriate doses and with qualifying criteria). A knowledgeable provider can prescribe off-label when the clinical case supports it and the patient provides informed consent.
How does GLP-1 therapy help insulin resistance in PCOS?
GLP-1 agonists improve insulin sensitivity by stimulating glucose-dependent insulin secretion, suppressing glucagon, reducing body weight, and decreasing hepatic fat. In PCOS, lowering chronically elevated insulin reduces the signal that drives ovarian androgen production — which is why metabolic improvement often precedes hormonal improvement. The key marker to track is HOMA-IR, which most patients see fall meaningfully within the first 8–12 weeks of treatment.
Can I get a GLP-1 medication for PCOS through telehealth?
Yes, though not all telehealth providers are equipped to manage PCOS specifically. Providers with women's health, endocrinology, or metabolic medicine focus are better suited to evaluate insulin resistance in PCOS context, order appropriate labs, and monitor response appropriately. Standard weight-loss telehealth platforms may not have the right clinical infrastructure. Expect to pay out of pocket — insurance coverage for off-label PCOS use is rare.
What labs should I get before starting a GLP-1 for PCOS insulin resistance?
Request baseline labs before starting: fasting insulin, fasting glucose, and HOMA-IR (the insulin resistance marker); free and total testosterone; LH, FSH; HbA1c; lipid panel; and liver function tests. These results confirm insulin resistance is present, establish a baseline for tracking progress, and screen for contraindications or complications. Follow-up at 3 and 6 months allows your provider to assess whether the medication is producing the expected metabolic improvements in your case.